ACADIA Pharmaceuticals Market Cap: 95.04M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ACAD Market Cap Rankings
| Overall | 22nd percentile | 3631 of 4673 |
| Sector | 29th percentile | 374 of 530 in Healthcare |
| Industry | 31st percentile | 113 of 164 in Biotechnology |
ACAD Market Cap Range, Past 5 Years
| Minimum | 104.41M | Jun 2004 |
| Maximum | 389.11M | Mar 2006 |
| Average | 211.34M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these ACAD related companies
ACAD News
ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
Feb 06, 9:00AM Business Wire
Feb 06, 9:00AM Business Wire
ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors
Jan 30, 9:00AM Business Wire
Jan 30, 9:00AM Business Wire
Unusual 11 Midday Movers 01/18: (UEPS) (CBRX) (AMSC) Higher; (COOL) (KUTV) (BXS) Lower
Jan 18, 2:12PM Street Insider
Jan 18, 2:12PM Street Insider
ACADIA Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011
Dec 07, 9:00AM Business Wire
Dec 07, 9:00AM Business Wire
ACADIA Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 9, 2011
Nov 02, 9:00AM Business Wire
Nov 02, 9:00AM Business Wire
$ACAD http://stks.co/cCR Update. Bullish MACD crossover. At resistance and near 20MA. Just needs volume.
about 122 days ago by VexTrades
about 122 days ago by VexTrades
$ACAD http://stks.co/bHc Big volume expansion. MACD cross on deck. Watch this one. Alerted lastnight.
about 123 days ago by VexTrades
about 123 days ago by VexTrades
ACADIA Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference on September 28, 2011
Sep 21, 9:00AM Business Wire
Sep 21, 9:00AM Business Wire
$ACAD http://stks.co/Bau Former runner. Popped through the 20MA and out of a wedge with higher lows.
about 152 days ago by VexTrades
about 152 days ago by VexTrades
ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
Sep 06, 9:00AM Business Wire
Sep 06, 9:00AM Business Wire
ACADIA Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 10, 2011
Aug 03, 9:00AM Business Wire
Aug 03, 9:00AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACAD | 1.80 | -0.01 | -0.55% | 95.04M |
| BCSI | 25.80 | 0.03 | 0.12% | 1.09B |
| COWN | 2.77 | -0.08 | -2.81% | |
| LVLT | 21.15 | -0.31 | -1.44% | 2.51B |
| ABVT | 69.42 | -0.61 | -0.87% | 1.79B |
| ROCM | 8.08 | 0.12 | 1.51% | 99.06M |
| ELON | 5.51 | -0.64 | -10.37% | 234.23M |
| BBOX | 28.57 | -0.34 | -1.18% | 505.12M |
| FMCN | 23.47 | -0.76 | -3.14% | 3.40B |
| PTIX | 1.99 | 0.11 | 5.85% | 22.13M |
